Participation of the SMAD2/3 signalling pathway in the down regulation of megalin/LRP2 by transforming growth factor beta (TGF-ß1)

Abstract

Megalin/LRP2 is a receptor that plays important roles in the physiology of several organs, such as kidney, lung, intestine, and gallbladder and also in the physiology of the nervous system. Megalin expression is reduced in diseases associated with fibrosis, including diabetic nephropathy, hepatic fibrosis and cholelithiasis, as well as in some breast and prostate cancers. One of the hallmarks of these conditions is the presence of the cytokine transforming growth factor beta (TGF-ß). Although TGF-ß has been implicated in the reduction of megalin levels, the molecular mechanism underlying this regulation is not well understood. Here, we show that treatment of two epithelial cell lines (from kidney and gallbladder) with TGF-ß1 is associated with decreased megalin mRNA and protein levels, and that these effects are reversed by inhibiting the TGF-ß1 type I receptor (TGF-ßRI). Based on in silico analyses, the two SMAD-binding elements (SBEs) in the megalin promoter are located at positions -57 and -605. Site-directed mutagenesis of the SBEs and chromatin immunoprecipitation (ChIP) experiments revealed that SMAD2/3 transcription factors interact with SBEs. Both the presence of SMAD2/3 and intact SBEs were associated with repression of the megalin promoter, in the absence as well in the presence of TGF-ß1. Also, reduced megalin expression and promoter activation triggered by high concentration of albumin are dependent on the expression of SMAD2/3. Interestingly, the histone deacetylase inhibitor Trichostatin A (TSA), which induces megalin expression, reduced the effects of TGF-ß1 on megalin mRNA levels. These data show the significance of TGF-ß and the SMAD2/3 signalling pathway in the regulation of megalin and explain the decreased megalin levels observed under conditions in which TGF-ß is upregulated, including fibrosis-associated diseases and cancer.

Metallothioneins and Megalin Expression Profiling in Premalignant and Malignant Oral Squamous Epithelial Lesions

“…Additionally, one population-based study linked polymorphisms within the megalin gene with the progression of prostate cancer [ 62 ]. Interestingly, megalin mRNA and protein levels were found to decrease in kidney and gallbladder epithelial cell lines upon in vitro activation of transforming growth factor-beta (TGF-ß1)—SMAD2/3 signaling pathway [ 63 ], which is well known for its tumor-suppressive effect [ 64 ]. As megalin is a multiligand receptor, to clarify its role in tumor growth, attention should be paid to its interaction with possible ligands.…”

IL-4 Receptor α Chain Protects the Kidney Against Tubule-Interstitial Injury Induced by Albumin Overload

“…Diwakar et al (2007) using OK cells showed that albumin induces TGF-β secretion. Recently, Cabezas et al (2019) using LLC-PK1 cells showed that TGF-β decreases megalin expression. Accordingly, we observed an increase in the TGFβ level in the BSA groups.…”

Chemical complementarity between immune receptors and cancer mutants, independent of antigen presentation protein binding, is associated with increased survival rates

“…LRP2 encodes the LDL receptor related protein, also termed megalin. LRP2/megalin plays a role in cellular signaling for growth pathways by facilitating endocytosis of various ligands including hormones, lipoproteins, vitamins, and sterols [25] . The TTN protein is a large protein found in muscle and is responsible for passive elasticity.…”